A pilot study assessing social support among cancer patients enrolled on clinical trials: a comparison of younger versus older adults

Paul J Novotny1
Denise J Smith1
Lorna Guse2
Teresa A Rumans3
Lynn Hartmann4
Steven Alberts4
Richard Goldberg5
David Gregory6
Mary Johnson7
Jeff A Sloan1

1Health Sciences Research, Mayo Clinic, Rochester, MN, USA; 2Faculty of Nursing, University of Manitoba, Winnipeg, Manitoba, Canada; 3Psychiatry, Mayo Clinic, Rochester, MN, USA; 4Medical Oncology, Mayo Clinic, Rochester, MN, USA; 5Oncology Services, University of North Carolina, Chapel Hill, NC, USA; 6Faculty of Health Sciences Nursing, University of Lethbridge, Lethbridge, Alberta, Canada; 7Chaplain Services, Mayo Clinic, Rochester, MN, USA

Purpose: This study tested the logistical feasibility of obtaining data on social support systems from cancer patients enrolled on clinical trials and compared the social support of older adults (age ≥65) and younger adults (<50 years of age) with cancer.

Methods: Patients had to be eligible for a phase II or phase III oncology clinical trial and enter the study prior to treatment. Patients filled out the Lubben Social Network Scale (LSNS) at baseline. The Symptom Distress Scale (SDS) and single-item overall quality of life (QOL) Uniscale were assessed at baseline and weekly for 4 weeks.

Results: There was no significant difference in overall mean Lubben social support levels by age. Older patients had more relatives they felt close to (85% versus 53% with 5 or more relatives, P = 0.02), heard from more friends monthly (84% versus 53% with 3 or more friends, P = 0.02), less overall symptom distress (P = 0.03), less insomnia (P = 0.003), better concentration (P = 0.005), better outlook (P = 0.01), and less depression (P = 0.005) than younger patients.

Conclusions: Younger subjects reported worse symptoms, a smaller social support network, and fewer close friends and relatives than older subjects. Having someone to discuss decisions and seeing friends or relatives often was associated with longer survival.

Keywords: social support, Lubben scale, QOL, elderly

Approximately 10.1 million individuals in this country have a history of cancer and 1,372,910 new individuals were diagnosed in the year 2006. The prevalence of cancer is about 13% in patients 18–49 and about 60% in ages 65 or over. Receiving a cancer diagnosis affects individuals in a multitude of ways. It is critical for cancer patients to have support, especially in light of the fear and social ‘stigma’ of cancer. The availability of support may decrease as a result of these issues and social networks of older people tend to be smaller than those of younger individuals. In previous studies in noncancer cohorts, better social support has been linked to longer survival times, lower hospitalization rates, better adjustment after diagnosis of disease, and better retention of cognitive function. More research is needed on the impact of social networks among cancer patients.

Studies have reported the positive effects of social support at the time of diagnosis and during adaptation to the disease. Conversely, cancer patients with diminished emotional support report more symptoms and lower QOL. Cancer patients have unique social support issues. For them, support from a spouse, immediate family, and peers are critical. The fear associated with cancer diagnosis and treatment increase the need for support, while at the same time the social stigma of having cancer can decrease the availability of support when it is most needed.
support models must be tailored to fit the specific needs of the individual because social support needs vary by treatment and stage of disease.11,14,16,22

The primary goal of this pilot study was to gain experience with assessing social support in cancer patients. This experience will lead to further studies of social networks in this cohort. The research hypotheses for this study were that the level of social support diminishes with age and has an impact on secondary goals. These secondary goals included symptoms captured by the SDS, mortality, and overall QOL.

Methods

Study design
The present study was a prospective, non-randomized cohort design. The accrual goal was 30 patients in each group. This sample size would provide 80% power to detect a difference of 0.7 of a standard deviation between the two groups. This effect size is considered a moderate to large effect size.23 Completion rates were calculated, with 80% completeness as a criterion for acceptability for further study.

Patients
This study was approved by the Mayo Foundation Institutional Review Board and participants provided informed consent. Patients had to be eligible for a Mayo phase II or III oncology clinical trial and had to be enrolled on this study prior to starting treatment for their primary malignant disease. Two groups of patients were entered on this study. Patients at least 18 years old and less than 50 years old were entered into a group considered young cancer patients, and patients at least 65 years old were entered into a group considered older adults. These two age groupings were selected to maximize the potential to demonstrate the effects of age on social support. Patients were enrolled between 7/16/1999 and 01/11/2002. Accruing younger patients proved more difficult at our institution, about twice as many patients age 65 or older go on phase II or III studies compared to patients less than age 50. Accrual for this younger cohort was stopped at 20 because of the slow accrual rate.

Measures

Lubben social network scale
The Lubben Social Network Scale (LSNS) is a validated self-reported 10 item scale measuring embedded support, perceived support, and the reciprocation of support.25–28 All 10 items are highly intercorrelated (Cronbach’s alpha = 0.70).29,30 Each question was scored on a zero to five scale with high scores indicating more social support. The overall LSNS social support score was calculated for each patient by summing the 10 questions. The LSNS was assessed at baseline before the patient started their cancer treatment. Our group recently used this same scale in a retrospective analysis of two lung cancer clinical trials to successfully demonstrate a lack of gender effect in social support among elderly patients.31 Differences in the individual LSNS questions were also analyzed.

The uniscale overall quality of life scale
The Uniscale32 tool used in this study was a single item visual analogue. Patients mark an ‘X’ along a bar to indicate their overall QOL. The bar ranges from ‘LOWEST QUALITY’ on the left side of the bar to ‘HIGHEST QUALITY’ on the right side of the bar. The patient’s score is the measured distance from the left of the bar to the ‘X’ divided by the total length of the bar times 100. Scores then range from 0 to 100 with 100 being the best possible score. The UNISCALE has been validated in cancer clinical trials.33 The Uniscale was assessed at baseline (before the start of treatment) and weekly for the remaining four weeks of the study.

The symptom distress scale
The Symptom Distress Scale (SDS)34 is a reliable and validated, self-reported 13-item questionnaire designed to identify physical and psychosocial symptoms of concern to patients and the degree of distress associated with each symptom. The scale has demonstrated convergent validity with the MOS-SF36 and discriminant validity has been established.35 The SDS was assessed at baseline (before the start of treatment) and weekly for the remaining four weeks of the study. For this and for all other patient-reported outcomes we translate scores onto a 0–100 point scale, where appropriate, so that higher scores always mean a positive indication for the patient (less pain or symptom distress, better quality of life).

Analysis plan
This prospective study compared social support, symptoms and QOL between the cohort of younger patients and the cohort of older patients. Secondary analyses included testing for gender differences. Fisher’s exact tests were used to test for differences in discrete variables between groups. Kruskal-Wallis tests were used to test differences in continuous variables between the two age groups,
Kaplan-Meier curves and log-rank tests were used to compare survival between the groups, and Spearman correlations were used to determine associations between social support and symptoms. Changes in symptoms and QOL over time were tested by applying t-tests to the differences between baseline and week 4 values.

Results

Demographics

Table 1 shows baseline demographics between the older and younger cohort. The baseline demographics were similar between the two groups. Almost all (93%) of the patients had late stage cancer.

LSNS form completion

During this 3-year period, 52 patients were enrolled in this study. Two patients did not provide any baseline information. Out of the 50 patients with baseline information, 41 (82%) filled out the LSNS. This completion percentage was sufficient to recommend the use of the LSNS in future studies of this patient population.

Age differences in social support networks

Table 2 and Figure 1 show LSNS by age group. There was no significant difference in overall mean LSNS by age (76.4 for younger patients, 80 for older patients, \( P = 0.49 \)). However, contrary to the pre-study hypothesis, younger patients had lower levels of social support than older patients on individual Lubben questions. Patients in the younger group were more likely relied on by others on a daily basis (69% vs 35%, \( P = 0.04 \)). Despite having advanced cancer, the younger patients had the added stress of being responsible for others. Patients \( \geq 65 \) years of age had more relatives they felt close to (85% vs 54% with \( > 4 \) relatives, \( P = 0.017 \)) and

<table>
<thead>
<tr>
<th>Table 1 Baseline characteristics by age group</th>
<th>Age &lt; 50 (N = 20)</th>
<th>Age ≥65 (N = 32)</th>
<th>Total (N = 52)</th>
<th>( P ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>Mean (SD)</td>
<td>42.3 (6.08)</td>
<td>71.2 (3.45)</td>
<td>60.1 (14.93)</td>
</tr>
<tr>
<td></td>
<td>Median</td>
<td>44.0</td>
<td>71.0</td>
<td>69.0</td>
</tr>
<tr>
<td></td>
<td>Range</td>
<td>29 to 49</td>
<td>65 to 80</td>
<td>29 to 80</td>
</tr>
<tr>
<td>Age group</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>26 to 30</td>
<td>1 (5%)</td>
<td>–</td>
<td>1 (2%)</td>
<td></td>
</tr>
<tr>
<td>31 to 35</td>
<td>3 (15%)</td>
<td>–</td>
<td>3 (6%)</td>
<td></td>
</tr>
<tr>
<td>36 to 40</td>
<td>3 (15%)</td>
<td>–</td>
<td>3 (6%)</td>
<td></td>
</tr>
<tr>
<td>41 to 45</td>
<td>6 (30%)</td>
<td>–</td>
<td>6 (12%)</td>
<td></td>
</tr>
<tr>
<td>46 to 50</td>
<td>7 (35%)</td>
<td>–</td>
<td>7 (13%)</td>
<td></td>
</tr>
<tr>
<td>65 to 70</td>
<td>–</td>
<td>16 (50%)</td>
<td>16 (31%)</td>
<td></td>
</tr>
<tr>
<td>71 to 75</td>
<td>–</td>
<td>12 (38%)</td>
<td>12 (23%)</td>
<td></td>
</tr>
<tr>
<td>76 to 80</td>
<td>–</td>
<td>4 (12%)</td>
<td>4 (8%)</td>
<td></td>
</tr>
<tr>
<td>Site</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GI</td>
<td>7 (35%)</td>
<td>13 (41%)</td>
<td>20 (38%)</td>
<td>0.13</td>
</tr>
<tr>
<td>GU</td>
<td>6 (30%)</td>
<td>4 (13%)</td>
<td>10 (19%)</td>
<td></td>
</tr>
<tr>
<td>Lung</td>
<td>1 (5%)</td>
<td>8 (25%)</td>
<td>9 (17%)</td>
<td></td>
</tr>
<tr>
<td>Breast</td>
<td>0 (0%)</td>
<td>2 (6%)</td>
<td>2 (4%)</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>6 (30%)</td>
<td>5 (16%)</td>
<td>11 (21%)</td>
<td></td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
<td></td>
<td>0.77</td>
</tr>
<tr>
<td>Missing</td>
<td>5</td>
<td>1</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Early (stage I, II)</td>
<td>1 (5%)</td>
<td>2 (7%)</td>
<td>3 (7%)</td>
<td></td>
</tr>
<tr>
<td>Late (stage III, IV)</td>
<td>18 (95%)</td>
<td>25 (93%)</td>
<td>43 (93%)</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
<td>0.76</td>
</tr>
<tr>
<td>Female</td>
<td>9 (45%)</td>
<td>13 (41%)</td>
<td>22 (42%)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>11 (55%)</td>
<td>19 (59%)</td>
<td>30 (58%)</td>
<td></td>
</tr>
<tr>
<td>Baseline QOL</td>
<td></td>
<td></td>
<td></td>
<td>0.36</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>74.4 (16.5)</td>
<td>77.0 (20.2)</td>
<td>76.0 (18.8)</td>
<td></td>
</tr>
</tbody>
</table>
Table 2 Lubben Social Network Scale levels by age group

<table>
<thead>
<tr>
<th>Lubben Social Network Score (0–100)</th>
<th>Age &lt; 50 (N = 20)</th>
<th>Age ≥ 65 (N = 32)</th>
<th>Total (N = 52)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean</td>
<td>76.4</td>
<td>80.0</td>
<td>78.7</td>
<td>0.49</td>
</tr>
<tr>
<td>SD</td>
<td>12.45</td>
<td>11.40</td>
<td>11.77</td>
<td></td>
</tr>
<tr>
<td>How many relatives do you see or hear from at least once a month? (NOTE: Include in-laws with relatives)</td>
<td></td>
<td></td>
<td></td>
<td>0.20</td>
</tr>
<tr>
<td>0</td>
<td>0%</td>
<td>4%</td>
<td>3%</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>13%</td>
<td>0%</td>
<td>5%</td>
<td></td>
</tr>
<tr>
<td>3–4</td>
<td>13%</td>
<td>12%</td>
<td>13%</td>
<td></td>
</tr>
<tr>
<td>5–8</td>
<td>27%</td>
<td>16%</td>
<td>20%</td>
<td></td>
</tr>
<tr>
<td>9 or more</td>
<td>47%</td>
<td>68%</td>
<td>60%</td>
<td></td>
</tr>
<tr>
<td>Tell me about the relative with whom you have the most contact. How often do you see or hear from that person?</td>
<td></td>
<td></td>
<td></td>
<td>0.67</td>
</tr>
<tr>
<td>Less than monthly</td>
<td>0%</td>
<td>4%</td>
<td>2%</td>
<td></td>
</tr>
<tr>
<td>Monthly</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td></td>
</tr>
<tr>
<td>A few times a month</td>
<td>7%</td>
<td>0%</td>
<td>2%</td>
<td></td>
</tr>
<tr>
<td>Weekly</td>
<td>13%</td>
<td>12%</td>
<td>12%</td>
<td></td>
</tr>
<tr>
<td>A few times a week</td>
<td>40%</td>
<td>38%</td>
<td>39%</td>
<td></td>
</tr>
<tr>
<td>Daily</td>
<td>40%</td>
<td>46%</td>
<td>44%</td>
<td></td>
</tr>
<tr>
<td>How many relatives do you feel close to? That is, how many of them do you feel at ease with, can talk to about private matters, or can call on for help?</td>
<td></td>
<td></td>
<td></td>
<td>0.02</td>
</tr>
<tr>
<td>0</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>13%</td>
<td>0%</td>
<td>5%</td>
<td></td>
</tr>
<tr>
<td>3–4</td>
<td>33%</td>
<td>15%</td>
<td>22%</td>
<td></td>
</tr>
<tr>
<td>5–8</td>
<td>33%</td>
<td>35%</td>
<td>34%</td>
<td></td>
</tr>
<tr>
<td>9 or more</td>
<td>20%</td>
<td>50%</td>
<td>39%</td>
<td></td>
</tr>
<tr>
<td>Do you have any close friends? That is, do you have friends with whom you feel at ease, can talk to about private matters, or can call on for help? If so, how many?</td>
<td></td>
<td></td>
<td></td>
<td>0.09</td>
</tr>
<tr>
<td>0</td>
<td>0%</td>
<td>4%</td>
<td>2%</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>0%</td>
<td>4%</td>
<td>2%</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>6%</td>
<td>8%</td>
<td>20%</td>
<td></td>
</tr>
<tr>
<td>3–4</td>
<td>33%</td>
<td>38%</td>
<td>37%</td>
<td></td>
</tr>
<tr>
<td>5–8</td>
<td>20%</td>
<td>19%</td>
<td>20%</td>
<td></td>
</tr>
<tr>
<td>9 or more</td>
<td>7%</td>
<td>27%</td>
<td>20%</td>
<td></td>
</tr>
<tr>
<td>How many of these friends do you see or hear from at least once a month?</td>
<td></td>
<td></td>
<td></td>
<td>0.02</td>
</tr>
<tr>
<td>0</td>
<td>7%</td>
<td>0%</td>
<td>2%</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>7%</td>
<td>4%</td>
<td>5%</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>33%</td>
<td>12%</td>
<td>20%</td>
<td></td>
</tr>
<tr>
<td>3–4</td>
<td>33%</td>
<td>31%</td>
<td>32%</td>
<td></td>
</tr>
<tr>
<td>5–8</td>
<td>13%</td>
<td>31%</td>
<td>24%</td>
<td></td>
</tr>
<tr>
<td>9 or more</td>
<td>7%</td>
<td>23%</td>
<td>17%</td>
<td></td>
</tr>
<tr>
<td>Tell me about the friend with whom you have the most contact. How often do you see or hear from that person?</td>
<td></td>
<td></td>
<td></td>
<td>0.25</td>
</tr>
<tr>
<td>Less than monthly</td>
<td>0%</td>
<td>0%</td>
<td>0%</td>
<td></td>
</tr>
<tr>
<td>Monthly</td>
<td>14%</td>
<td>4%</td>
<td>8%</td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
more friends they heard from monthly (85% vs 54% with 2 friends, \( P = 0.016 \)).

**Age differences in symptoms**

Figure 2 shows that older patients reported fewer symptoms than the younger patients. Older patients reported less overall symptom distress (mean of 86 vs 77, \( P = 0.03 \)), less insomnia (11% vs 47% with frequent trouble sleeping, \( P = 0.003 \)), better concentration (81% vs 40% with their normal ability to concentrate, \( P = 0.005 \)), better outlook (86% vs 40% with little or no worries, \( P = 0.01 \)), and less depression (74% vs 27% seldom feel depressed, \( P = 0.005 \)).

**Social support levels and symptoms by gender**

There were no significant differences in overall social support levels by gender (mean overall LSNS scores of 81 for females vs 77 males, \( P = 0.40 \)). However, females
were more likely to see close relatives daily (70% vs 19%, \(P = 0.0027\)) and were more likely to have other people discuss their problems with them (60% of women reported “very often” or “always” compared to only 25% of men, \(P = 0.02\)). Women reported more overall symptom distress at baseline (mean overall SDS score of 78 vs 86 for men, \(P = 0.02\)) and a higher frequency of SDS pain (10% of women almost never had pain vs 59% of men, \(P = 0.005\)).

Figure 1 Age by total Lubben Social Network Scale (LSNS) score. Spearman correlation = −0.05 (\(P = 0.78\)).

Figure 2 Mean baseline symptoms by age group. *Indicates significant differences at \(P < 0.05\).
Age differences in QOL
There were no statistically significant differences in baseline quality of life or changes in quality of life by age group or gender.

Age differences in survival
There were no statistically significant differences in survival times by age group (log-rank \( P = 0.98 \)). There was no a survival difference even after adjusting for stage of disease and gender (Cox model \( P = 0.60 \)).

Social support and survival
Due to the small sample size and the lack of a survival difference, the two age cohorts were combined to explore the relationship between social support and survival. Some levels of the LSNS questions were also combined because of the sparse responses in some levels. As shown in Figure 3, always having someone to talk to about decisions was a significant predictor for survival even after adjusting for age and gender (Cox proportional hazard \( P = 0.01 \), hazard ratio = 0.31, 95% confidence interval for the odds ratio of 0.002 to 0.492). For this analysis, patients with responses of ‘often’ and ‘very often’ were combined and compared to patients responding with ‘always’.

Correlations between social support and symptoms
There was a modest correlation between symptoms and how often they saw their closest friend (-0.50 correlation with overall SDS, and 0.51 correlation with fatigue).

Changes in symptoms and QOL over time.
There were no significant differences in the changes in symptoms or QOL over time by age group. The combined cohort of patients in both age groups showed a significant decrease in QOL over time (mean decrease of 7.9, \( P = 0.02 \)), a decrease in pain frequency (mean improvement of 0.4, \( P = 0.02 \)), and a decrease in SDS outlook (mean decrease -0.3, \( P = 0.04 \)).

Discussion
Social support networks are important factors in the health of the elderly.\(^{36,37}\) Better social support networks have been linked with patient survival, overall health, their ability to carry out routine daily tasks, and their ability to cope with major life events and disease.\(^{5,38–40}\) Patients can become very isolated after a cancer diagnosis due to the social stigma associated with cancer, but this is the time these patients need the most support, and their level of support is associated with outcome. Recent evidence has emerged that both supports the importance of social networks on

![Figure 3 Overall survival by having someone to discuss issues.](image-url)
health and challenges the notion that older adults are more isolated.

This study suggests there may be a generational gap in the level of social support experienced by cancer patients. In this study, younger patients tended to have smaller support networks and fewer close friends. Younger patients also reported higher levels of symptoms. These results were in perfect opposition to our research hypothesis. The reasons for these results should be explored further. It is possible that the younger patients do not have a spouse or partner to lean on or their parents or other family members around for support. Their friends are younger and may be busy with their own careers and families. The rapid growth of internet social networks may also have resulted in an increase in the size of social networks, but a decrease in face-to-face social skills and therefore less direct social networking among younger adults. The effects of internet networking on cancer patients, requires further investigation. It is also possible that older patients had developed social networks as they aged in response to previous illness and disability and that these established social networks were maintained. Younger patients would be less likely to have developed and maintained similar social networks. The younger patients also were more likely to be relied on by others on a daily basis. This likely meant the patients had the added burden of dealing with how their cancer will affect their young children or a spouse.

Age group and gender were not significant factors for survival in this study. These results are not terribly surprising in that the impact of age group and gender on survival is variable across patient populations and clinical studies. However, there was some evidence that having someone to discuss decisions with and being able to see friends and relatives often was linked to longer survival. This is an intriguing result that requires further investigation.

This study suggests that cancer patients may benefit from a system that fosters positive, supportive social networks. Social networking with close trusted friends and relatives should be encouraged, as these interactions promote improved quality of life and longer survival. Cancer health providers should be aware of the potential for social isolation and its effects on cancer patients. Future interventions could include screening for insufficient social networks, enhancing and encouraging existing social networks, and connecting isolated patients to potential social links. The quality of these social networks also needs to be considered. Social supports need to be positive, supportive and tailored to the individual.

A methodological note from this study indicates that the LSNS was easy for participants to complete and provided reasonably detailed data on the relative well-being of patient social networks. In particular, the use of individual item analysis provided supplementary insights that could not be garnered from the total score. This is a phenomenon that has been seen in other studies and is a particular focus of the research program of the senior author. These findings have supported the examination of results for individual items within a summated score since changes in individual items may be lost among the summated scores of multi-item assessments.

A limitation of this study is that the patients were all from cancer clinical trials. Patients going on clinical trials are only a small fraction of all cancer patients and they may have higher levels of support than other patients. Higher levels of support are likely needed for patients on clinical trials to support the extra trips and expenses. The findings may be magnified in patients not able to participate in a clinical trial.

Future research
The data suggest that social networks can be successfully evaluated in cancer patients. More definitive studies are needed into the differences in social support networks between age groups, the impact of social networks on patient outcomes, and the impact of identifying and alleviating social isolation. Future plans include testing an intervention targeted at improving social networks in patients identified as having low social support. A “menu” of support services will be assembled by the investigators and provided to patients to see if patients that receive structured, active encouragement and information from an enhanced social network will report higher QOL, fewer symptoms, and improved toxicity profiles. Future studies will also include patients in the middle age group (50 to 64).

Acknowledgment of financial support
This study was conducted as a collaborative trial of the Mayo Clinic and was supported in part by Public Health Service grants CA-25224, CA-37404, CA-63848, CA-63849, and CA-35195. The authors report no conflicts of interest in this work.

Disclosures
The authors report no conflicts of interest in this work.
References


